Berliner Boersenzeitung - Once-taboo ketamine booms for US at-home mental care

EUR -
AED 4.32537
AFN 75.977092
ALL 95.601615
AMD 439.296871
ANG 2.108079
AOA 1080.01836
ARS 1597.362148
AUD 1.645993
AWG 2.119992
AZN 2.01118
BAM 1.955341
BBD 2.372144
BDT 144.796008
BGN 1.964646
BHD 0.444067
BIF 3501.975218
BMD 1.177774
BND 1.498175
BOB 8.13809
BRL 5.87909
BSD 1.177774
BTN 109.891867
BWP 15.801961
BYN 3.352913
BYR 23084.360737
BZD 2.368744
CAD 1.613897
CDF 2715.945806
CHF 0.922627
CLF 0.026532
CLP 1044.236873
CNY 8.034241
CNH 8.036261
COP 4257.392118
CRC 539.319181
CUC 1.177774
CUP 31.210998
CVE 110.23912
CZK 24.330033
DJF 209.729668
DKK 7.472991
DOP 70.519432
DZD 155.60956
EGP 60.977341
ERN 17.666603
ETB 183.905641
FJD 2.612657
FKP 0.867993
GBP 0.871158
GEL 3.174121
GGP 0.867993
GHS 12.983952
GIP 0.867993
GMD 85.977777
GNF 10333.4515
GTQ 9.006886
GYD 246.412153
HKD 9.213546
HNL 31.289311
HRK 7.531626
HTG 154.166898
HUF 364.903652
IDR 20174.965732
ILS 3.52994
IMP 0.867993
INR 109.589763
IQD 1542.883294
IRR 1555838.802756
ISK 144.006597
JEP 0.867993
JMD 185.984234
JOD 0.835051
JPY 187.551602
KES 152.215434
KGS 102.996058
KHR 4722.29235
KMF 493.486947
KPW 1060.007665
KRW 1744.953944
KWD 0.36325
KYD 0.98147
KZT 555.499591
LAK 25983.900044
LBP 105674.678119
LKR 371.982674
LRD 216.699128
LSL 19.327504
LTL 3.477659
LVL 0.712423
LYD 7.443631
MAD 10.877331
MDL 20.127275
MGA 4890.059612
MKD 61.626608
MMK 2473.755996
MNT 4229.66724
MOP 9.493771
MRU 47.004927
MUR 54.424995
MVR 18.196219
MWK 2045.792916
MXN 20.322187
MYR 4.6628
MZN 75.324483
NAD 19.327626
NGN 1579.253223
NIO 43.343505
NOK 11.030573
NPR 175.834651
NZD 2.001773
OMR 0.452847
PAB 1.177724
PEN 4.051949
PGK 5.104235
PHP 70.66527
PKR 328.479474
PLN 4.240314
PYG 7507.556251
QAR 4.294747
RON 5.095637
RSD 117.367489
RUB 89.951713
RWF 1719.54932
SAR 4.418156
SBD 9.464087
SCR 16.298205
SDG 707.842151
SEK 10.831489
SGD 1.499718
SHP 0.879327
SLE 29.061584
SLL 24697.31704
SOS 673.070564
SRD 44.168798
STD 24377.53368
STN 24.851021
SVC 10.304581
SYP 130.175969
SZL 19.327113
THB 37.747739
TJS 11.170578
TMT 4.128096
TND 3.398468
TOP 2.835796
TRY 52.827383
TTD 8.000122
TWD 37.185801
TZS 3075.425741
UAH 51.460304
UGX 4351.978334
USD 1.177774
UYU 47.008964
UZS 14326.636692
VES 564.928338
VND 31010.77644
VUV 139.528842
WST 3.198774
XAF 655.83088
XAG 0.014996
XAU 0.000246
XCD 3.182992
XCG 2.122502
XDR 0.815643
XOF 655.83088
XPF 119.331742
YER 281.075422
ZAR 19.333553
ZMK 10601.376314
ZMW 22.524668
ZWL 379.242589
  • CMSD

    -0.1300

    22.9

    -0.57%

  • RBGPF

    -13.5000

    69

    -19.57%

  • BCC

    -0.1100

    78.8

    -0.14%

  • NGG

    -0.3400

    87.52

    -0.39%

  • RIO

    1.1500

    99.71

    +1.15%

  • CMSC

    -0.0900

    22.62

    -0.4%

  • BCE

    0.3400

    24.16

    +1.41%

  • RYCEF

    -0.4400

    17.1

    -2.57%

  • JRI

    0.0300

    12.91

    +0.23%

  • GSK

    -0.6800

    57.13

    -1.19%

  • RELX

    0.5300

    36.21

    +1.46%

  • AZN

    -0.7400

    200.47

    -0.37%

  • VOD

    0.1100

    15.7

    +0.7%

  • BTI

    -0.5400

    56.14

    -0.96%

  • BP

    1.5100

    47.63

    +3.17%

Once-taboo ketamine booms for US at-home mental care
Once-taboo ketamine booms for US at-home mental care

Once-taboo ketamine booms for US at-home mental care

Americans are paying to get a star of the psychedelic medicine movement –- ketamine -– shipped to them for at-home mental health treatments that are being called both a breakthrough and a gamble.

Text size:

A pandemic-spurred easing of prescription rules helped fuel a jump in telemedicine offerings of ketamine, an anesthetic that was once a taboo party drug but has become a buzzed-about tool against depression.

Yet long-term, large-scale studies of ketamine's medical impact are limited, leaving some experts concerned that an unregulated online boom could result in mishaps or a regulatory crackdown.

"This has to be rolled out slowly," said Boris Heifets, a Stanford University assistant professor of anesthesiology. "The risk is that we are scaling the fix but not the solution, which is a much more integrated approach to mental health."

Ketamine has been available in the United States since the 1970s as an anesthetic called a "dissociative" because of the hallucinogenic effects that have helped make it a rave culture drug.

It's legal for US doctors to prescribe, while some other psychedelics getting renewed attention for mental health uses like LSD or MDMA (also called ecstasy) are classified as having no medical utility and a high risk for abuse.

In this context, recent years have seen an uptick in clinics offering in-person intravenous ketamine treatments for depression, anxiety or chronic pain, though regulations and practices vary across American states.

- Ketamine 'babysitter' -

Then came the pandemic, which resulted in US authorities allowing doctors to remotely prescribe drugs like ketamine that previously required an in-person visit.

An increasing number of companies, some already doing in-clinic treatments, began offering to evaluate clients online and to send the drugs for home use to approved candidates.

Nue Life, which launched about a year ago, is one of those firms. Its CEO Juan Pablo Cappello estimated it has served over 3,000 ketamine patients so far.

"If you actually drill down on the sort of potentials for abuse here, you realize of course they exist, but we're creating a standard of care to make that quite unlikely," he told AFP.

For example, he noted clients are instructed to have an adult "babysitter" watch over them for the roughly 90 minutes the drug experience lasts, and he reasoned that people simply looking for ketamine could get it cheaper on the street.

Clients of the service, which costs $1,250 for a package providing six ketamine experiences, are encouraged but not obligated to couple it with therapy, Cappello said.

"The at-home telemedicine model, I would argue, is actually safer and more effective for patients," allowing more patients "to actually take advantage of these therapies," he added.

Heifets, the Stanford researcher, noted that making ketamine more available carries risks -- including the chances that authorities would tighten access if an at-home treatment resulted in some sort of tragedy.

- 'Change your life' -

US regulators in 2019 approved a type of ketamine specifically for adults with treatment-resistant depression, though with stringent rules like requiring patients to be monitored by a health care provider for at least two hours after their dose.

Americans have "a hair trigger for problem-solving through litigation," Heifets noted of the potential for lawsuits if things go wrong.

He was part of a team that analyzed the real-world effectiveness of intravenous ketamine therapy -- which can involve higher doses than the at-home services –- and reported most patients improved, though about eight percent said depressive symptoms worsened after treatment.

"We have very, very little evidence for our understanding of how effective ketamine is for depression at scale," he added.

Yet for people like 36-year-old New Yorker Philip Markle, who underwent an at-home treatment with a company called Mindbloom, ketamine is a profoundly useful tool.

Over his long battle with depression, the performer and comedian has tried medication, psychedelics like LSD, and talk therapy since the age of 12, but found something unique in ketamine.

Rather than the short-lived sense of change other treatments provided, ketamine imparted a sense of clarity and of helpful self-acceptance -– not the heavy effects he'd experienced with other psychedelics.

"It felt like if any drug could be administered through the mail, and you could do a psychedelic that could change your life, on your own, this would be the one," he told AFP.

(B.Hartmann--BBZ)